A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause

NCT07829653 | Not Yet Recruiting Phase 3

• 1 other identifier: 2693-CL-0315
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is for women in India who are going through menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS). Fezolinetant is a medicine to treat hot flashes in women going through menopause. It is currently approved in more than 40 countries, including the US and countries in Europe. Further studies are needed before it is approved for use in India. The aim of this study is to confirm if fezolinetant can help reduce hot flashes in Indian women. Women who want to take part in the study will be given an electronic device or use the app on their own smartphone to track their hot flashes and night sweats. The women will record this information before, during and after taking the study treatment. All the women in the study will take 1 tablet of fezolinetant once a day for up to 12 weeks. During the study, the women will visit the study clinic several times. The researchers will collect information about the women's health and ask about their hot flashes and night sweats. At each visit, they will also be asked if they have any medical problems. The women will have a follow up visit 3 weeks after taking their last tablet of study treatment, to collect information about their health and symptoms. Each woman will be in this study for about 5 months.

Conditions

Hot Flashes

Keywords

menopause; vasomotor symptoms; ESN364; fezolinetant; VEOZAH™

Outcome Measures

Primary Outcomes (1)

• Mean change from baseline in the frequency of moderate to severe vasomotor symptoms (VMS)

  Frequency of moderate and severe VMS events will be calculated as sum of moderate and severe VMS events per day.

  Baseline and week 12

Secondary Outcomes (16)

• Mean change from baseline in the frequency of moderate to severe VMS

  Baseline and up to week 12

• Mean change from baseline in the severity of moderate to severe VMS

  Baseline and up to week 12

• Mean percent reduction in the frequency of moderate to severe VMS

  Baseline and up to week 12

• Percent reduction ≥ 50% in the frequency of moderate to severe VMS

  Baseline and up to week 12

• Percent reduction of 100% in the frequency of moderate to severe VMS

  Baseline and up to week 12

Study Arms (1)

Fezolinetant

EXPERIMENTAL

Participants will receive fezolinetant once daily for 12 weeks.

Drug: Fezolinetant

Interventions

Fezolinetant DRUG

Oral

Also known as: ESN364, VEOZAH™

Fezolinetant

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant has a body mass index ≥ 17 kg/m\^2 and ≤ 38 kg/m\^2 at screening visit.
• Participant must be seeking treatment or relief for VMS associated with menopause and confirmed as menopausal, defined as meeting 1 of the following criteria for natural or surgical menopause at the screening visit:
• Spontaneous amenorrhea for ≥ 12 consecutive months
• Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (FSH \> 40 IU/L); or
• Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit (with or without hysterectomy).
• FSH \> 40 IU/L if participants received hysterectomy but still have an ovary/ovaries.
• Within the 10 days prior to start of active treatment, participant must have a minimum average of 7 moderate to severe hot flashs (VMS) per day (data must be available for at least 7 of the last 10 days prior to treatment).
• Participant is in good general health as determined on the basis of medical history and general physical examination, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and ECG within the reference range for the population studied, or showing no clinically relevant deviations.
• Participant has a negative urine pregnancy test at screening; this is not required for participants who have had a total hysterectomy.
• Participant has a negative serology panel (i.e., negative hepatitis B surface antigen \[HBsAg\], negative hepatitis C virus antibody \[HCVAb\] and negative human immunodeficiency virus antibody \[HIVAb\] screens) at screening.
• Participant agrees not to participate in another interventional study while participating in the present study.

You may not qualify if:

• Participant has known substance abuse or alcohol addiction within 6 months of screening.
• Participant has a history of malignancy with the exception of at least 5 years post treatment and without known recurrence.
• Participant has a current malignancy, with the exception of non-metastatic basal cell carcinoma of the skin.
• Participant has a history within the last 6 months prior to screening of undiagnosed uterine bleeding.
• Participant has a medical condition or chronic disease (including history of neurological \[including cognitive\], hepatic, renal, cardiovascular, gastrointestinal, pulmonary \[e.g., moderate asthma\], endocrine, or gynecological disease) or malignancy that could confound interpretation of the study outcome.
• Participant has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months, or who is at significant risk to commit suicide.
• Participant has previously been enrolled in a clinical trial with fezolinetant or other neurokinin (NK) receptor antagonists.
• Participant uses a prohibited therapy (strong and moderate CYP \[cytochrome P450\] 1A2 inhibitors, systemic hormone replacement therapy \[HRT\], or hormonal contraceptive, or any treatment for VMS \[prescription, over the counter, off-label or herbal\]) or is not willing to wash-out and discontinue use of such drugs for the full duration of study conduct.
• Participant has received any investigational therapy within 35 days or 5 half-lives, whichever is longer, prior to screening.
• Participant has uncontrolled hypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure as ≥ 90 mmHg based on an average of 2 to 3 readings within the screening period.
• Participants with a medical history of hypertension who are well controlled may be enrolled.
• Participants who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures.
• Participant has active liver disease, jaundice, elevated liver aminotransferases (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]), elevated total bilirubin (TBL) or direct bilirubin (DBL), elevated international normalized ratio (INR) or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 x upper limit of normal (ULN) can be enrolled if TBL are normal. Patients with mildly elevated ALP (up to 1.5 x ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated TBL may be enrolled as long as hemolysis is ruled-out (i.e., DBL, hemoglobin and reticulocytes are normal).
• Participant has creatinine \> 1.5 × ULN; or estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula ≤ 30 mL/min per 1.73 m\^2 at screening.
• Participant has any condition which makes the participant unsuitable for study participation.

Sponsors & Collaborators

• Astellas Pharma Inc: lead

MeSH Terms

Conditions

Hot Flashes

Interventions

fezolinetant

Condition Hierarchy (Ancestors)

Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Associate Mecial Director

  Astellas Pharma Global Development, Inc.

  STUDY DIRECTOR

Central Study Contacts

Astellas Pharma Inc.

CONTACT

800-888-7704; Astellas.registration@astellas.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 15, 2026
• First Posted: September 21, 2026
• Study Start (Estimated): October 31, 2026
• Primary Completion (Estimated): March 31, 2028
• Study Completion (Estimated): April 30, 2028
• Last Updated: September 28, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, CSR
• Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
• Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.